Clinical Trial Update: The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy, safety, and immunogenicity of an insulin glargine biosimilar (Sansulin Log-G) compared to Lantus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Lantus (insulin glargine)
• Sansulin Log-G (insulin glargine biosimilar)

Snippet

Sponsor: Indonesia University | Conditions: Diabetes Mellitus | Phase 2 | Status: UNKNOWN